Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fexofenadine Hydrochloride
Therapeutic Area : Urology
Study Phase : Phase II
Recipient : Columbia University
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Antihistamines on Ureteral Stent-Related Symptoms
Details : Fexofenadine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Nephrolithiasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2021
Lead Product(s) : Fexofenadine Hydrochloride
Therapeutic Area : Urology
Highest Development Status : Phase II
Recipient : Columbia University
Deal Size : Inapplicable
Deal Type : Inapplicable